English
Regional settings| Spread | 8.96 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ ¥5,000 Short position overnight fee ~ ¥4,000 | -0.011244% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ ¥5,000 Short position overnight fee ~ ¥4,000 | -0.010978% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | JPY | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | Japan | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 1508.15 |
| Open | 1512.14 |
| 1-Year Change | -25.68% |
| Day's Range | 1512.14 - 1529.8 |
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
BRIEF: For the nine months ended 31 December 2021, Astellas Pharma Inc revenues increased 5% to Y992.29B. Net income applicable to common stockholders decreased less than 1% to Y132.49B. Revenues reflect Sales of Pharmaceuticals segment increase of 6% to Y971.11B, Other Business segment increase of 33% to Y14.07B, Americas segment increase of 15% to Y407.94B, Estabridge segment increase of 10% to Y239.22B.
04/2005, Company merged with Fujisawa Pharmaceutical Co., Ltd. & Name Changed from Yamanouchi Pharmaceutical Co., Ltd. FY'08 1Q&Q3 WAS & DWAS estimated and WAS used as O/S. FY'09 Q3,12 Q2 DWAS estimated.
